

Christopher J Edwards

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6335599/publications.pdf>

Version: 2024-02-01

58
papers

1,417
citations

535685

17
h-index

388640

36
g-index

62
all docs

62
docs citations

62
times ranked

2217
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally. <i>Arthritis Care and Research</i> , 2022, 74, 1623-1630.	1.5	3
2	Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients. <i>Rheumatology</i> , 2022, 61, 1035-1043.	0.9	6
3	Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies: incidence using different testing criteria, and case series. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 298-303.	0.4	1
4	Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies: incidence using different testing criteria, and case series.. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 298-303.	0.4	0
5	P244â€fThe use of anti-malarial therapy in UK Rheumatology practice. A UK-based pilot survey for the BILAG group. <i>Rheumatology</i> , 2022, 61, .	0.9	0
6	P246â€fRevision to musculoskeletal domain of BILAG-2004 index to incorporate ultrasound findings. <i>Rheumatology</i> , 2022, 61, .	0.9	0
7	2019 EULAR points to consider for the assessment of competences in rheumatology specialty training. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 65-70.	0.5	12
8	A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2021, 8, 167-181.	1.1	6
9	Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 305-317.	6.3	145
10	Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study. <i>Rheumatology</i> , 2021, 60, 5194-5204.	0.9	16
11	O10â€fCharacteristics of patients who discontinued baricitinib treatment within 12 months and reasons for discontinuation: real-world data. <i>Rheumatology</i> , 2021, 60, .	0.9	3
12	O33â€fBaricitinib in the BSRBR-RA registry: characteristics and status of patients at first follow-up. <i>Rheumatology</i> , 2021, 60, .	0.9	1
13	Lupus, vaccinations and COVID-19: What we know now. <i>Lupus</i> , 2021, 30, 1541-1552.	0.8	21
14	TNF inhibitors for the prevention of Alzheimerâ€™s disease: Preliminary findings from the rheumatoid arthritis medication and memory study (RESIST). <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
15	Descriptive epidemiology of hip and knee replacement in rheumatoid arthritis: An analysis of UK electronic medical records. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 237-244.	1.6	12
16	An Analysis of Real-World Data on the Safety of Etanercept in Older Patients with Rheumatoid Arthritis. <i>Drugs and Aging</i> , 2020, 37, 35-41.	1.3	2
17	Clinical management of Lupus patients during the COVID-19 pandemic. <i>Lupus</i> , 2020, 29, 1661-1672.	0.8	15
18	Hydroxychloroquine and coronavirus disease 19. <i>Lupus</i> , 2020, 29, 669-670.	0.8	0

#	ARTICLE	IF	CITATIONS
19	O23â€¦Ixekizumab (IXE) vs. adalimumab (ADA) for the treatment of PSA: 52-week efficacy and safety outcomes. <i>Rheumatology</i> , 2020, 59, .	0.9	0
20	Efficacy and Safety of Etanercept in Elderly Patients with Rheumatoid Arthritis: A Post-Hoc Analysis of Randomized Controlled Trials. <i>Drugs and Aging</i> , 2019, 36, 853-862.	1.3	5
21	E062â€¦Baseline characteristics of patients with rheumatoid arthritis starting the janus kinase inhibitor baricitinib: real-life observation study. <i>Rheumatology</i> , 2019, 58, .	0.9	1
22	Impact of TNF inhibitor therapy on joint replacement rates in rheumatoid arthritis: a matched cohort analysis of BSRBR-RA UK registry data. <i>Rheumatology</i> , 2019, 58, 1168-1175.	0.9	13
23	242â€¦Baseline characteristics of patients with lupus nephritis requiring rituximab therapy: results from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR). <i>Rheumatology</i> , 2019, 58, .	0.9	0
24	Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1001-1014.	1.4	18
25	Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1â€¦3 pooled analysis. <i>Arthritis Research and Therapy</i> , 2019, 21, 118.	1.6	55
26	Predicting disease progression and poor outcomes in patients with moderately active rheumatoid arthritis: a systematic review. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz002.	0.3	9
27	The effect of rheumatoid arthritis on patient-reported outcomes following knee and hip replacement: evidence from routinely collected data. <i>Rheumatology</i> , 2019, 58, 1016-1024.	0.9	11
28	Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus. <i>Rheumatology</i> , 2019, 58, 304-312.	0.9	28
29	Apremilast monotherapy in DMARD-naïve psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. <i>Rheumatology</i> , 2018, 57, 1253-1263.	0.9	72
30	Trends and determinants of length of stay and hospital reimbursement following knee and hip replacement: evidence from linked primary care and NHS hospital records from 1997 to 2014. <i>BMJ Open</i> , 2018, 8, e019146.	0.8	97
31	Association between NICE guidance on biologic therapies with rates of hip and knee replacement among rheumatoid arthritis patients in England and Wales: An interrupted time-series analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 605-610.	1.6	21
32	Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial. <i>Rheumatology</i> , 2018, 57, 84-91.	0.9	17
33	Patient-reported outcomes and safety in patients undergoing synovial biopsy: comparison of ultrasound-guided needle biopsy, ultrasound-guided portal and forceps and arthroscopic-guided synovial biopsy techniques in five centres across Europe. <i>RMD Open</i> , 2018, 4, e000799.	1.8	31
34	The impact of rheumatoid arthritis on the risk of adverse events following joint replacement: a real-world cohort study. <i>Clinical Epidemiology</i> , 2018, Volume 10, 697-704.	1.5	18
35	Inflammation and dementia: Using rheumatoid arthritis as a model to develop treatments?. <i>Autoimmunity Reviews</i> , 2018, 17, 919-925.	2.5	40
36	Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1â€¦3 studies. <i>RMD Open</i> , 2018, 4, e000669.	1.8	31

#	ARTICLE	IF	CITATIONS
37	What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2018, 22, 1-258.	1.3	17
38	Switching to biosimilar infliximab: real world data in patients with severe inflammatory arthritis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 171-172.	0.4	9
39	Characteristics of hand involvement in a comparative study of two early <sc>RA</sc> cohorts from the <sc>UK</sc> and <sc>C</sc>hina. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1426-1436.	0.9	3
40	Both rare and common ERAP1 allotypes have distinct functionality defined by polymorphic context and are important in AS association. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E1575-E1576.	3.3	5
41	Randomized Controlled Trial of Rituximab and Cost Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2017, 69, 1440-1450.	2.9	194
42	Dosing down with biologic therapies: a systematic review and clinicians' perspective. <i>Rheumatology</i> , 2017, 56, 1847-1856.	0.9	59
43	190. RHEUMATOID ARTHRITIS, A STUDY OF CONTINUOUS MONITORING OF PHYSICAL ACTIVITY USING SMARTPHONES. <i>Rheumatology</i> , 2017, 56, .	0.9	0
44	The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis. <i>Rheumatology</i> , 2016, 55, 1837-1842.	0.9	19
45	Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1065-1073.	0.5	225
46	Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1268-1271.	0.5	26
47	Are there dangers in biologic dose reduction strategies?. <i>Autoimmunity Reviews</i> , 2016, 15, 742-746.	2.5	6
48	125 An Exploration of the Characteristics of Early Rheumatoid Arthritis Hand Involvement Among Different Gender, Age and Hand-Dominance in a Chinese Population. <i>Rheumatology</i> , 2016, , .	0.9	0
49	Can the publication of guidelines change the management of early rheumatoid arthritis? An interrupted time series analysis from the United Kingdom. <i>Rheumatology</i> , 2015, 54, kev268.	0.9	11
50	Are guidelines good value for money?: Fig. 1. <i>Rheumatology</i> , 2015, 54, kev308.	0.9	0
51	Does Combined Clinical and Ultrasound Assessment Allow Selection of Individuals With Rheumatoid Arthritis for Sustained Reduction of Anti-Tumor Necrosis Factor Therapy?. <i>Arthritis Care and Research</i> , 2015, 67, 746-753.	1.5	24
52	Raising the quality of rheumatology management recommendations: lessons from the EULAR process 10 years after provision of standard operating procedures. <i>Rheumatology</i> , 2015, 54, 1392-1396.	0.9	5
53	Reply to Robinson and Brown: It is the combination of ERAP1 allotypes that identifies individuals with Ankylosing Spondylitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1817-E1817.	3.3	1
54	Phase I studies: the role of publicly funded academic-healthcare partnerships. <i>BMJ</i> , The, 2015, 351, h3889.	3.0	0

#	ARTICLE	IF	CITATIONS
55	Functionally distinct <i>ERAP1</i> allotype combinations distinguish individuals with Ankylosing Spondylitis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17594-17599.	3.3	90
56	The reliability of a novel magnetic resonance imaging-based tool for the evaluation of forefoot bursae in patients with rheumatoid arthritis: the FFB score. Rheumatology, 2014, 53, 2014-2017.	0.9	6
57	The BILAG-2004 index is associated with development of new damage in SLE. Rheumatology, 0, , .	0.9	0
58	Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine. Rheumatology, 0, , .	0.9	2